Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS

B. J. Dezube, A. B. Pardee, B. Chapman, Laurel A Beckett, J. A. Korvick, W. J. Novick, J. Chiurco, P. Kasdan, C. M. Ahlers, L. T. Ecto, C. S. Crumpacker

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Tumor necrosis factor-α (TNF)-cachectin increases the expression of the human immunodeficiency virus (HIV), reverses the therapeutic efficacy of zidovudine (ZDV), and may contribute to the wasting syndrome. Pentoxifylline (Trental) decreases TNF activity; in cell culture, it decreases HIV replication and down-regulates expression of the HIV long terminal repeat (LTR). Therefore, pentoxifylline was administered to 25 patients with advanced AIDS in this AIDS Clinical Trial Group study (ACTG 160), the goal of which was to investigate the ability of the drug to decrease TNF expression and HIV replication in this patient population. One patient discontinued drug treatment because of toxicity. Data were analyzed on the 17 patients who completed the 8-week study treatment with pentoxifylline, 400 mg, thrice daily. The median pretreatment CD4+ lymphocyte count was 32 cells/mm3. Fasting serum triglycerides, which have previously been shown to correlate with levels of interferon-α and/or TNF, fell on average by 66 mg/dl (p = 0.06). TNF mRNA levels in peripheral blood mononuclear cells fell in 10 of 16 patients (p = 0.02). HIV load decreased and increased significantly in four and one patients, respectively, but did not change in the group as a whole. This study demonstrates the safety of pentoxifylline in AIDS patients and its ability to decrease triglycerides and TNF mRNA levels.

Original languageEnglish (US)
Pages (from-to)787-794
Number of pages8
JournalJournal of Acquired Immune Deficiency Syndromes
Volume6
Issue number7
StatePublished - 1993
Externally publishedYes

Fingerprint

Pentoxifylline
Acquired Immunodeficiency Syndrome
Triglycerides
Tumor Necrosis Factor-alpha
Serum
HIV
Aptitude
Virus Replication
HIV Long Terminal Repeat
Wasting Syndrome
Messenger RNA
Zidovudine
CD4 Lymphocyte Count
Pharmaceutical Preparations
Interferons
Fasting
Blood Cells
Therapeutics
Down-Regulation
Cell Culture Techniques

ASJC Scopus subject areas

  • Virology
  • Immunology and Allergy

Cite this

Dezube, B. J., Pardee, A. B., Chapman, B., Beckett, L. A., Korvick, J. A., Novick, W. J., ... Crumpacker, C. S. (1993). Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. Journal of Acquired Immune Deficiency Syndromes, 6(7), 787-794.

Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. / Dezube, B. J.; Pardee, A. B.; Chapman, B.; Beckett, Laurel A; Korvick, J. A.; Novick, W. J.; Chiurco, J.; Kasdan, P.; Ahlers, C. M.; Ecto, L. T.; Crumpacker, C. S.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 6, No. 7, 1993, p. 787-794.

Research output: Contribution to journalArticle

Dezube, BJ, Pardee, AB, Chapman, B, Beckett, LA, Korvick, JA, Novick, WJ, Chiurco, J, Kasdan, P, Ahlers, CM, Ecto, LT & Crumpacker, CS 1993, 'Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS', Journal of Acquired Immune Deficiency Syndromes, vol. 6, no. 7, pp. 787-794.
Dezube, B. J. ; Pardee, A. B. ; Chapman, B. ; Beckett, Laurel A ; Korvick, J. A. ; Novick, W. J. ; Chiurco, J. ; Kasdan, P. ; Ahlers, C. M. ; Ecto, L. T. ; Crumpacker, C. S. / Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. In: Journal of Acquired Immune Deficiency Syndromes. 1993 ; Vol. 6, No. 7. pp. 787-794.
@article{d3c6baafa6bc4d429b2e260648e6bba1,
title = "Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS",
abstract = "Tumor necrosis factor-α (TNF)-cachectin increases the expression of the human immunodeficiency virus (HIV), reverses the therapeutic efficacy of zidovudine (ZDV), and may contribute to the wasting syndrome. Pentoxifylline (Trental) decreases TNF activity; in cell culture, it decreases HIV replication and down-regulates expression of the HIV long terminal repeat (LTR). Therefore, pentoxifylline was administered to 25 patients with advanced AIDS in this AIDS Clinical Trial Group study (ACTG 160), the goal of which was to investigate the ability of the drug to decrease TNF expression and HIV replication in this patient population. One patient discontinued drug treatment because of toxicity. Data were analyzed on the 17 patients who completed the 8-week study treatment with pentoxifylline, 400 mg, thrice daily. The median pretreatment CD4+ lymphocyte count was 32 cells/mm3. Fasting serum triglycerides, which have previously been shown to correlate with levels of interferon-α and/or TNF, fell on average by 66 mg/dl (p = 0.06). TNF mRNA levels in peripheral blood mononuclear cells fell in 10 of 16 patients (p = 0.02). HIV load decreased and increased significantly in four and one patients, respectively, but did not change in the group as a whole. This study demonstrates the safety of pentoxifylline in AIDS patients and its ability to decrease triglycerides and TNF mRNA levels.",
author = "Dezube, {B. J.} and Pardee, {A. B.} and B. Chapman and Beckett, {Laurel A} and Korvick, {J. A.} and Novick, {W. J.} and J. Chiurco and P. Kasdan and Ahlers, {C. M.} and Ecto, {L. T.} and Crumpacker, {C. S.}",
year = "1993",
language = "English (US)",
volume = "6",
pages = "787--794",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "7",

}

TY - JOUR

T1 - Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS

AU - Dezube, B. J.

AU - Pardee, A. B.

AU - Chapman, B.

AU - Beckett, Laurel A

AU - Korvick, J. A.

AU - Novick, W. J.

AU - Chiurco, J.

AU - Kasdan, P.

AU - Ahlers, C. M.

AU - Ecto, L. T.

AU - Crumpacker, C. S.

PY - 1993

Y1 - 1993

N2 - Tumor necrosis factor-α (TNF)-cachectin increases the expression of the human immunodeficiency virus (HIV), reverses the therapeutic efficacy of zidovudine (ZDV), and may contribute to the wasting syndrome. Pentoxifylline (Trental) decreases TNF activity; in cell culture, it decreases HIV replication and down-regulates expression of the HIV long terminal repeat (LTR). Therefore, pentoxifylline was administered to 25 patients with advanced AIDS in this AIDS Clinical Trial Group study (ACTG 160), the goal of which was to investigate the ability of the drug to decrease TNF expression and HIV replication in this patient population. One patient discontinued drug treatment because of toxicity. Data were analyzed on the 17 patients who completed the 8-week study treatment with pentoxifylline, 400 mg, thrice daily. The median pretreatment CD4+ lymphocyte count was 32 cells/mm3. Fasting serum triglycerides, which have previously been shown to correlate with levels of interferon-α and/or TNF, fell on average by 66 mg/dl (p = 0.06). TNF mRNA levels in peripheral blood mononuclear cells fell in 10 of 16 patients (p = 0.02). HIV load decreased and increased significantly in four and one patients, respectively, but did not change in the group as a whole. This study demonstrates the safety of pentoxifylline in AIDS patients and its ability to decrease triglycerides and TNF mRNA levels.

AB - Tumor necrosis factor-α (TNF)-cachectin increases the expression of the human immunodeficiency virus (HIV), reverses the therapeutic efficacy of zidovudine (ZDV), and may contribute to the wasting syndrome. Pentoxifylline (Trental) decreases TNF activity; in cell culture, it decreases HIV replication and down-regulates expression of the HIV long terminal repeat (LTR). Therefore, pentoxifylline was administered to 25 patients with advanced AIDS in this AIDS Clinical Trial Group study (ACTG 160), the goal of which was to investigate the ability of the drug to decrease TNF expression and HIV replication in this patient population. One patient discontinued drug treatment because of toxicity. Data were analyzed on the 17 patients who completed the 8-week study treatment with pentoxifylline, 400 mg, thrice daily. The median pretreatment CD4+ lymphocyte count was 32 cells/mm3. Fasting serum triglycerides, which have previously been shown to correlate with levels of interferon-α and/or TNF, fell on average by 66 mg/dl (p = 0.06). TNF mRNA levels in peripheral blood mononuclear cells fell in 10 of 16 patients (p = 0.02). HIV load decreased and increased significantly in four and one patients, respectively, but did not change in the group as a whole. This study demonstrates the safety of pentoxifylline in AIDS patients and its ability to decrease triglycerides and TNF mRNA levels.

UR - http://www.scopus.com/inward/record.url?scp=0027153107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027153107&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 787

EP - 794

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 7

ER -